Company presentation - Mondobiotech

More documents

Recommendations

Info

Stock snapshot Reported capital Commercial register Listed share capital (in units) 1'327'805 Share capital (in units) 54'229'365 Listed share capital CHF 132'781 Share capital CHF 661'797 Conditional capital (in units) 3'269'413 Conditional capital CHF 326'941 Authorised capital (in units) 3'190'279 Authorised capital CHF 319'028 Shares detail Valor symbol RARE Trading 26.08.2009 - Valor number 10'191'073 Security type Registered share ISIN CH0101910732 Trading currency CHF Security segment Swiss Shares Exchange SIX Swiss Exchange Primary listed yes Product line Mid & Small Caps Swiss Shares Issued by mondoBIOTECH holding AG Regulatory standard Main Standard Number in issue 1'327'805 Clearing via SegaInterSettle AG Nominal value 0.10 Settlement currency CHF Dividend entitlement 1x per year R ARE SIX Swiss Exchange Symbol Index member SPI SXI Bio+Medtech SPI Extra SXI Life Sciences SPI ex SLI Swiss All Share Index Sarasin Swiss IPO Index Stock value on July 27th, 2010 at 5pm: CHF 73.00 Market Cap on July 27th, 2010 at 5pm: CHF 483.11 million Stock quote online www.six-swiss-exchange.com/shares/security_info_en.html?id=CH0101910732CHF4 22/33
Share capital structure A corporate structure to ensure stability and a long time horizon: • The original investors and co-founders own the unlisted share majority with privileged voting rights in order to underscore their commitment. • The community can also hold a financial stake in the company by purchasing SIX Swiss Exchange listed shares. • This dual share structure generates stability in the long term and ensures the company’s leadership team maintains the ability to continue the innovative approach that has characterized the company from the outset without it suffering from an unfriendly take-over or any other form of control oriented speculation. • Google, The New York Times, The Washington Post, The Wall Street Journal, Roche and Berkshire Hathaway (a Warren Buffett’s subsidiary) are all examples of companies having a similar capital structure. 23/33
Page 1 and 2: Introduction to our business, Augus
Page 3 and 4: The context 30’000 is the total n
Page 5 and 6: Value drivers of our business • I
Page 7 and 8: Key competitive strength Dry search
Page 9 and 10: Model validation For our vision, bu
Page 11 and 12: Search & Match 312 medicaments for
Page 13 and 14: IP protection & orphan market exclu
Page 15 and 16: Licensed pipeline Search & Match Pa
Page 17 and 18: Licensed products Secretin to Lung
Page 19 and 20: Products for licensing MPC at advan
Page 21: WR Hambrecht+Co. • Founded in 199
Page 25 and 26: Financial data - segment reporting
Page 27 and 28: Financial Calendar Next Corporate A
Page 29 and 30: Board Robert Edward Patterson Manag
Page 31 and 32: About us • We started the Company
Page 33: Mondobiotech Holding AG DasKloster

Company presentation - Mondobiotech

Create successful ePaper yourself

Delete template?

Save as template?